Publication | Closed Access

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

UrologyMoxibustionGastroenterologyDouble-blind Galaxi-1 TrialMaintenance ResultsUlcerative ColitisPhase 2MedicineDigestive System Diseases